Medicare

Politics Rachel Cohrs

STAT Plus: Medicare explains how it will choose drugs for negotiation

Politics John Wilkerson

STAT Plus: Would the federal government defer to states to regulate PBMs?

Politics Rachel Cohrs

STAT Plus: Biden administration to fine manufacturers of 27 medicines for price hikes

Politics John Wilkerson

STAT Plus: PhRMA chief dings health insurers over drug prices at their own conference

Business Bob Herman and Casey Ross

STAT Plus: Buyer’s remorse: How a Medicare Advantage business is strangling one of its first funders

Politics Joanne Silberner

STAT Plus: Medicare will take R&D costs, effectiveness into account when it negotiates drug prices. But studies show that doesn’t affect prices

Politics Rachel Cohrs

STAT Plus: An unlikely new 340B alliance emerges between PhRMA and community health centers

Politics John Wilkerson

STAT Plus: Medicare chief on the new drug price negotiation program’s operations, hiring, and timelines

Politics Rachel Cohrs

STAT Plus: Biden proposes expanding Medicare drug negotiation program

Insurance John Wilkerson

STAT Plus: The other way the government is privatizing Medicare

First Opinion Cynthia A. Fisher

New analysis: CMS vastly overestimates hospital price transparency efforts

Insurance Bob Herman

STAT Plus: DaVita faces another probe over ties to kidney care charity

First Opinion David Mitchell

STAT Plus: Another pharma industry flip-flop: Claims about the IRA’s effect on small-molecule versus biologic drugs

Hospitals John Wilkerson

STAT Plus: Here’s another sign the Biden administration is taking a harsher stance on hospital consolidation

Insurance Bob Herman

STAT Plus: Medicare Advantage membership grows 7% for 2023

Politics Sarah Owermohle

STAT Plus: Doctors’ top lobbyist in Washington on Medicare money, burnout, and private equity

Politics Rachel Cohrs and John Wilkerson

STAT Plus: Biden administration pitches 3 big new drug pricing reform experiments

Politics Rachel Cohrs

STAT Plus: Medicare advisers suggest tweaks to coverage process for Alzheimer’s drugs

Politics John Wilkerson

STAT Plus: Generics companies fought to stop the new drug pricing law. But they may end up benefiting

First Opinion MacKay Jimeson

State of the Union highlights America’s awkward conversation on financing the development of new medicines

Insurance Bob Herman and Tara Bannow

STAT Plus: CVS’ Oak Street Health acquisition continues the industry’s provider obsession

Biotech Rachel Cohrs

STAT Plus: How one biotech investor is changing his calculus now that Medicare can negotiate drug prices

Business Bob Herman

STAT Plus: Biden administration floats major 2024 pay cut for Medicare Advantage plans

Insurance Bob Herman and Tara Bannow

STAT Plus: Medicare Advantage insurers will score $2 billion gift thanks to limited audits

Politics John Wilkerson

STAT Plus: Medicare may test policy of paying less for accelerated approval drugs

Insurance Bob Herman and Tara Bannow

STAT Plus: Medicare Advantage insurers to repay billions under final federal audit rule

Insurance Bob Herman

STAT Plus: ‘Everybody has blood on their hands’: A decade-long battle over Medicare Advantage audits is coming to a head

Exclusive Sarah Owermohle

STAT Plus: HHS’ Becerra on enrolling in Medicare, annual Covid vaccines, and seniors’ mental health

Politics Rachel Cohrs

STAT Plus: The unexpected alliance lobbying for Medicare to pay for new obesity drugs